April 28th 2025
The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.
April 25th 2025
The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.
While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.
April 17th 2025
Four tips for midsized companies when entering new global markets.
March 21st 2025
The pharmaceutical company had previously been subjected to a 2-year suspension.
Open For Debate
Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems
Doing More With Less
In order to take a big step forward, GSK looks to employ smaller licensing deals and business units
Jumping the Gun
Britain's new approach to drug pricing isn't as bad as the industry feared.
British Biotech Blues
Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right?
Fire and NICE
UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs
Hits Like a BRIC
The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.
Contamination Alert
Tainted batches of Viracept pulled from European shelves.
Five-Year Survivor: European Edition
Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different"
Global Report: Single-Source Supply
Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service
Global Report: Ready ... Set ...
The UK has benefited from the stem-cell debate in the US. Several scientists have fled to Europe's more favorable regulatory stance.
Back Page: Of Movies and Drugs
A free flow of cheap counterfeits eclipses the ability of local manufacturers to create new products.
Global Report: Please Come Back
A new European collaboration of biotech, pharma, academia, and government takes up the challenge of boosting R&D.
Global Report: A Hope and a Payer
One health insurance company in The Netherlands is offering doctors a financial incentive to prescribe generic statins and proton pump inhibitors. Doctors and patients complained, but a court upheld the practice.
Global Report: The UK's New Code of Conduct
Serious offenders of the new Association of the British Pharmaceutical Industry's Code of Practice can be "named and shamed" with adverts in the trade press. Details of breaches by companies will be posted online.
Global Report: Still Waiting
Traders say parallel distribution of drugs generates savings for patients. Industry says it creates more profits for traders, leaving pharma with less R&D funding.